ArticleScientific reports2025
The effect of defocus incorporated multiple segment spectacles' lenses combined with different concentrations atropine for myopia control.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Diffractive optical element (D.O.E) spectacle lenses for myopia prevention and control: a small-scale pilot study among younger Chinese children.BMJ open ophthalmology · 2026Trial
- Adjunctive 0.05% Atropine for Children with Continued Rapid Myopia Progression During Defocus Incorporated Multiple Segments Spectacle Lens Treatment: A Retrospective Matched Cohort Study.Ophthalmology and therapy · 2026Article
- Comparative efficacy of twice-daily 0.01% atropine combined with Orthokeratology versus DIMS lenses in myopia control: an elastic net penalized regression analysis.BMC ophthalmology · 2026Article
- Reduced myopia progression with low-dose atropine in DIMS non-responders and evidence of altered pupillary light reflex kinetics.Scientific reports · 2026Article
- Current Evidence on Options and Efficacy of Combination Therapy for Myopia Control-A Narrative Review.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Review
- Myopia as a Global Public Health Challenge a Narrative Review.Life (Basel, Switzerland) · 2026Review
- Comparison of effectiveness of four myopia control interventions in Chinese children: a real-world retrospective study.Eye and vision (London, England) · 2026Article
- Myopia Management Consensus Statement in South Korean Children 2025 by the Korean Myopia Society for the Korean Association for Pediatric Ophthalmology and Strabismus.Korean journal of ophthalmology : KJO · 2026Review
- Two-year results of Lenslet-ARray-Integrated spectacle lenses for myopia control in children.Eye and vision (London, England) · 2025Article
- Article
- The Myopic Control Effect of Defocus Incorporated Multiple Segments' Spectacle Lens With Atropine in High Myopia Population.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aim to evaluate the myopia control effect of defocus incorporated multiple segments' (DIMS) spectacle lens in combination with different concentrations of atropine (ATR). A retrospective cohort study was conducted and DIMS users were categorized according to ATR concentration: 55 DIMS alone, 55 DIMS-Low ATR (0.01%) and 50 DIMS-High ATR (0.125%) groups. All three myopia control methods were applied for one year. Primary outcomes measures were changes in spherical equivalent refraction (SER) and axial length (AXL). One-way ANOVA was utilized to compare the outcome differences among the three groups, and multiple linear regression was utilized to analyze the effects of age, sex, baseline SER and baseline AXL on myopia progression among the three groups. The cycloplegic SER progression was-0.30 ± 0.25 D, -0.17 ± 0.49 D and - 0.16 ± 0.14 D in DIMS, DIMS-Low ATR and DIMS-High ATR groups respectively. The DIMS group showed a significant higher cycloplegia SER progression (P = 0.003). The AXL elongation was 0.13 ± 0.08 mm, 0.06 ± 0.20 mm and 0.06 ± 0.14 mm in DIMS, DIMS-Low ATR and DIMS-High ATR groups respectively and AXL elongation was significantly higher in DIMS group (P = 0.011). The young age demonstrated positive correlation to the higher cycloplegia SER progression in all groups (all P < 0.05). The young age is also correlated to higher AXL elongation in the DIMS and DIMS-Low ATR groups (both P < 0.05). The myopia control effects of low- and high-concentration ATRs in DIMS users show no significant difference, while the addition of atropine in combination with DIMS spectacles had a greater effect on myopia control than DIMS spectacles alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.